BioPharmSignal logoBioPharmSignal

Biotech News

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

Enliven Therapeutics (ELVN)Enliven TherapeuticsClinical readout

Enliven will host a webcast conference call on June 11, at 8:30 a.m. ET BURLINGAME, Calif., June 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small

Open original release

Related news

ELVNEnliven Therapeutics2026-05-12 13:53 EST

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

KYMRKymera2026-06-09 11:00 EST

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

RVMDRevolution Medicines2026-05-31 12:06 EST

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

EXELExelixis2026-05-19 12:00 EST

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

NRIXNurix Therapeutics2026-05-14 20:06 EST

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

RVMDRevolution Medicines2026-05-06 22:00 EST

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

REPLReplimune Group2026-05-30 12:00 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

GERNGeron2026-05-12 13:31 EST

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

View all latest news

Enliven Therapeutics

Enliven Therapeutics is an oncology company focused on targeted therapies and precision cancer medicine. Its development strategy emphasizes genetically defined cancers and differentiated molecules.

Recent company news

ELVNEnliven Therapeutics2026-06-03 20:05 EST

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

ELVNEnliven Therapeutics2026-05-21 20:05 EST

Enliven Therapeutics to Present at Upcoming Investor Conferences

ELVNEnliven Therapeutics2026-05-12 13:53 EST

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

ELVNEnliven Therapeutics2026-03-03 21:05 EST

Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Stock data

Close
52.74 USD
Market cap
2.16B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States